Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Show more

Location: 10275 Science Center Dr., Suite 1710, San Diego, CA, 92121, United States | Website: https://zentalis.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

83.46M

52 Wk Range

$1.01 - $5.44

Previous Close

$1.16

Open

$1.14

Volume

1,157,666

Day Range

$1.13 - $1.27

Enterprise Value

-206.8M

Cash

332.5M

Avg Qtr Burn

-37.88M

Insider Ownership

13.58%

Institutional Own.

80.34%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Azenosertib (ZN-c3) (oral inhibitor of WEE1) +/- niraparib Details
Ovarian cancer, Cancer, PARPi Resistant Ovarian Cancer

Phase 2

Data readout

Azenosertib (ZN-c3) (oral inhibitor of WEE1) mono Details
Cyclin E1+ platinum-resistant ovarian cancer (PROC)

Phase 2

Data readout

Phase 2

Data readout

Phase 1b

Data readout

Azenosertib (ZN-c3) (oral inhibitor of WEE1) w/ multiple chemo Details
Ovarian cancer, Cancer, Platinum-resistant ovarian cancer

Phase 1b

Update

Phase 1

Update

Azenosertib (ZN-c3) (oral inhibitor of WEE1) Details
Ovarian cancer, Cancer, Platinum Sensitive Ovarian Cancer

Phase 1

Update

Failed

Discontinued

Failed

Discontinued

ZN-d5 (oral selective inhibitor of B-cell lymphoma 2 (BCL-2)) Details
Cancer, relapsed or refractory light chain amyloidosis

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued